Biomarker results suggest PrimeC may be acting on shared neurodegeneration mechanisms, adding weight to growing shift in brain aging research.
What if ALS, Alzheimer’s and Parkinson’s aren’t entirely separate diseases after all?
Isn’t it that, for many years, we have treated neurodegenerative disorders as distinct conditions, each with its own causes, symptoms and treatment strategies? Alzheimer’s steals memories. ALS robs muscles of movement. Parkinson’s affects balance and coordination. Different diseases, different drugs – or so the thinking has largely gone. However, that neat separation is beginning to blur.
NeuroSense Therapeutics has announced positive biomarker findings from its Phase 2 RoAD proof-of-concept study of PrimeC in Alzheimer’s disease [1]. PrimeC wasn’t originally designed for Alzheimer’s; it was developed for amyotrophic lateral sclerosis (ALS). Yet the company says the biological changes now seen in Alzheimer’s resemble those previously observed in its ALS program, hinting that different neurodegenerative diseases may be driven by more shared biology than previously appreciated.
Instead of viewing these disorders as isolated illnesses, scientists are increasingly asking whether they’re different expressions of the same underlying breakdown in the aging brain. Also, that shift reflects growing dissatisfaction with another long-standing assumption in medicine, that drug development has largely followed a simple formula: identify one biological target, build one drug against it and hope the disease slows down. That approach has produced important advances, particularly in infectious diseases and cancer. Alzheimer’s, however, has proven stubbornly resistant.
Rather than being caused by one faulty mechanism, Alzheimer’s resembles a city where multiple systems begin failing at once. Proteins misfold, inflammation rises, cells struggle to clear waste, energy production falters and communication between neurons gradually breaks down. Repairing one road doesn’t necessarily solve the traffic jam.
PrimeC is built around a different philosophy. Instead of focusing on a single pathway, the oral therapy combines two FDA-approved drugs into one extended-release treatment designed to influence several biological processes linked to neurodegeneration simultaneously.
The latest findings don’t prove that approach works clinically, but they do suggest the drug is interacting with the biology researchers hoped it would.
The RoAD trial was deliberately modest. Eight participants with Alzheimer’s disease were randomly assigned to receive either PrimeC or a placebo, allowing researchers to evaluate safety while exploring early biological effects. Rather than asking whether patients remembered more words or performed better on cognitive tests, investigators looked at biomarkers – measurable molecules in blood and cerebrospinal fluid that act like biological fingerprints, revealing what’s happening inside the brain long before outward changes become obvious.
Researchers observed changes in several biomarkers commonly associated with Alzheimer’s, including those linked to tau and amyloid proteins. They also reported changes in proteins often found alongside Alzheimer’s that have been associated with more aggressive disease progression.
Just as notable was the broader pattern. According to NeuroSense, many of the biomarker shifts mirrored those previously seen when PrimeC was studied in ALS, suggesting the therapy may be influencing biological processes shared across multiple neurodegenerative diseases rather than targeting Alzheimer’s alone.
The company also reported no serious adverse events or unexpected safety concerns, consistent with previously announced safety data from the trial.
Alon Ben-Noon, co-founder and CEO of NeuroSense, said that the initial findings from the RoAD study are encouraging because they may suggest that the same multi-target mechanism the company has been advancing in ALS is engaging biology that is also central to Alzheimer’s disease.
“This was a small, exploratory proof-of-concept study with a limited number of analyzable patient samples, and so we are appropriately measured about what it can tell us on its own. But seeing biological signals that point in the same direction across two distinct neurodegenerative diseases strengthens our conviction in PrimeC’s underlying approach and helps inform the design of a next, adequately powered study,” Ben-Noon added.
Researchers have increasingly recognized that Alzheimer’s rarely exists in isolation. Many patients also develop other age-related brain changes, with different disease processes overlapping rather than occurring independently. That growing understanding is reflected in comments from Prof. Steven E. Arnold, Professor of Neurology at Harvard Medical School and member of NeuroSense’s Scientific Advisory Board.
He explained that because Alzheimer’s disease is driven by multiple interacting pathological processes, single-target therapies frequently fall short. He noted that the biomarker findings in the first treated Alzheimer’s patient suggested broad proteostatic effects, which are consistent with PrimeC’s proposed mechanism of action.
“Of course, these are the very first biomarker data of PrimeC treatment in AD and should be interpreted with that in mind. They do, however, support the rationale for evaluating PrimeC in a larger, well-controlled trial designed to test whether these biological effects replicate and, more importantly, translate into meaningful clinical benefit,” Arnold said.
His remarks echo a growing conversation across longevity science. Aging isn’t generally understood as a single process, but as a network of interconnected biological changes that unfold together over time. If aging itself is multifaceted, it follows that diseases rooted in aging may require therapies capable of working across several pathways at once.
The RoAD study remains exactly what it was designed to be: an exploratory proof-of-concept trial. With just eight participants, it cannot answer whether PrimeC slows Alzheimer’s progression or preserves cognition. Larger, well-controlled studies will be needed before those questions can be addressed. Still, the findings offer a glimpse of a changing research philosophy.
Instead of asking whether a treatment belongs to the ALS field or the Alzheimer’s field, researchers are increasingly asking whether it targets the shared biology that sits beneath both. Instead of searching for a single molecular culprit, they’re beginning to acknowledge that aging brains may need therapies capable of restoring several failing systems at once.
That may ultimately prove to be the bigger story. The future of neurodegenerative medicine may not lie in drawing sharper lines between Alzheimer’s, ALS and Parkinson’s, but in recognizing where those lines disappear. For longevity science, whose central ambition is preserving function rather than merely extending years, that represents more than a new therapeutic strategy; it signals a shift from treating diseases in isolation to treating the biology of aging itself.
